Results 121 to 130 of about 3,683 (169)

A Rare Case of Fabry's Disease-Induced Cardiomyopathy: A Case Report and Review of the Literature. [PDF]

Cureus
Hussein A, Salih A, Mohamed Y, Thames E, Buja LM.   +4 more
europepmc   +1 more source

Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease. [PDF]

Mol Genet Metab Rep
Okamoto H, Goto S, Fujita M, Fujii H.
europepmc   +1 more source

Marine Lectins in Innate Immune Modulation: Mechanistic Insights, Signaling Pathways, and a Cross-Taxa Evidence Landscape. [PDF]

Mar Drugs
Hong CE, Lyu SY.
europepmc   +1 more source

Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy. [PDF]

Int J Mol Sci
Grimaldi A, Auletta A, Ciurli F, Aiello V, Vischini G, Fabbrizio B, Becherucci F, Pasquinelli G, La Manna G, Capelli I, Mignani R.   +10 more
europepmc   +1 more source

Progress and Challenges in the Treatment of Fabry Disease. [PDF]

BioDrugs
Lenders M, Menke ER, Brand E.
europepmc   +1 more source

Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experience. [PDF]

Mol Genet Metab Rep
McCarron EP, Chinnadurai R, Stepien KM, Bassett J, Meyer J, Sharma R, Woolfson P, Jovanovic A.   +7 more
europepmc   +1 more source

Concomitant immunoglobulin A nephropathy and membranous nephropathy with Fabry-like zebra bodies: A case report and literature review. [PDF]

Medicine (Baltimore)
Dai Y, Lu C, Bi G, Zhou G, Wang R.
europepmc   +1 more source

Sex-based antibody subclass maturation drives direct enzymatic inhibition in fabry disease patients receiving enzyme replacement therapy. [PDF]

Front Mol Biosci
Baldwin T, Kurdi H, Doykov I, Robertson F, Rosmini S, Nordin S, Augusto J, Kozor R, Baruteau J, Davison J, Moreno-Martinez D, Ramaswami U, Vijapurapu R, Geberhiwot T, Steeds R, Moon J, Hughes D, Mills K, Heywood WE.   +18 more
europepmc   +1 more source